BBHC
KRYS icon

Brown Brothers Harriman & Co’s Krystal Biotech KRYS Stock Holding History

Brown Brothers Harriman & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,000
Closed -$1.62M – 1181
2020
Q4 		$1.62M Hold
27,000
– – 0.01% 176
2020
Q3 		$1.16M Hold
27,000
– – 0.01% 197
2020
Q2 		$1.12M Buy
+27,000
New +$1.3M 0.01% 192

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Brown Brothers Harriman & Co's KRYS Position: Q1 2021 in Review

Brown Brothers Harriman & Co sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 27,000 shares — an estimated $1.62M sold.

Brown Brothers Harriman & Co first reported a position in KRYS in Q2 2020 and held it in 3 quarters. The position peaked at $1.62M in Q4 2020. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

  • Brown Brothers Harriman & Co reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 27,000 Krystal Biotech shares in Q1 2021, an estimated $1.62M.
  • Brown Brothers Harriman & Co first reported a position in Krystal Biotech in Q2 2020 and held it in 3 quarters.
  • Brown Brothers Harriman & Co's Krystal Biotech position peaked at $1.62M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2021, filed 13 May 2021.